Generic Nithiodote Availability
Last updated on Apr 10, 2024.
Nithiodote is a brand name of sodium nitrite/sodium thiosulfate, approved by the FDA in the following formulation(s):
NITHIODOTE (sodium nitrite; sodium thiosulfate - solution, solution;intravenous, intravenous)
-
Manufacturer: HOPE PHARMS
Approval date: January 14, 2011
Strength(s): 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) [RLD]
Has a generic version of Nithiodote been approved?
No. There is currently no therapeutically equivalent version of Nithiodote available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nithiodote. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Sodium thiosulfate-containing pharmaceutical compositions
Patent 10,479,686
Issued: November 19, 2019
Inventor(s): Sherman Craig & Smith Catherine Marie & Wirtz Kevin Robert & Schulze Erich
Assignee(s): Hope Medical Enterprises, Inc.Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
Patent expiration dates:
- July 7, 2030✓✓
- July 7, 2030
-
Patent 11,753,301
Patent expiration dates:
- February 10, 2030✓✓✓
- February 10, 2030
-
Sodium thiosulfate-containing pharmaceutical compositions
Patent 8,496,973
Issued: July 30, 2013
Inventor(s): Sherman Craig & Smith Catherine Marie & Wirtz Kevin Robert & Schulze Erich
Assignee(s): Hope Medical Enterprises, Inc.Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
Patent expiration dates:
- March 29, 2031✓✓✓
- March 29, 2031
-
Sodium nitrite-containing pharmaceutical compositions
Patent 8,568,793
Issued: October 29, 2013
Inventor(s): Sherman Craig & Lepine Anthony James & Smith Catherine Marie & Wirtz Kevin Robert & Schulze Erich
Assignee(s): Hope Medical Enterprises, Inc.Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.
Patent expiration dates:
- December 24, 2031✓✓
- December 24, 2031
-
Sodium thiosulfate-containing pharmaceutical compositions
Patent 9,345,724
Issued: May 24, 2016
Inventor(s): Sherman Craig & Smith Catherine Marie & Wirtz Kevin Robert & Schulze Erich
Assignee(s): Hope Medical Enterprises, Inc.Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
Patent expiration dates:
- July 7, 2030✓✓✓
- July 7, 2030
-
Sodium thiosulfate-containing pharmaceutical compositions
Patent 9,585,912
Issued: March 7, 2017
Inventor(s): Sherman Craig & Smith Catherine Marie & Wirtz Kevin Robert & Schulze Erich
Assignee(s): Hope Medical Enterprises, Inc.Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
Patent expiration dates:
- July 7, 2030✓✓
- July 7, 2030
-
Sodium nitrite-containing pharmaceutical compositions
Patent 9,687,506
Issued: June 27, 2017
Inventor(s): Sherman Craig & Lepine Anthony James & Smith Catherine Marie & Wirtz Kevin Robert & Schulze Erich
Assignee(s): Hope Medical Enterprises, Inc.Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.
Patent expiration dates:
- February 10, 2030✓✓
- February 10, 2030✓✓
- February 10, 2030
More about Nithiodote (sodium nitrite/sodium thiosulfate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: antidotes
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.